USPTO serial 97812964
SEQUEL
Reviewed by CopyMark Law Group
Status 732Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- STIGLITZ, SUSAN R
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with SEQUEL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $849*
Plus Government fees of $1,050
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
MARK E. TETREAULT
340 COMMERCIAL STREETMANCHESTER, NH 03101United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Infusion cartridges sold pre-filled with medication for medical use in the field of cardiovascular disease, diabetes, asthma, kidney disease, and cancer; Adhesive overlays in the nature of adhesive medical tape and adhesive bandages for use with infusion pumps and associated devices, all of the foregoing for use in connection with a device for the delivery of therapeutic agents for the treatment of disease | ACTIVE | — |
| 009 | Software as a Medical Device (SaMD), downloadable, for predicting blood analyte levels and adjusting infusion pump settings based on personalized data for use in connection with a device for the delivery of therapeutic agents for the treatment of disease; Downloadable educational mobile applications featuring information and instruction on managing, treating and living with chronic disease; batteries; battery chargers | ACTIVE | — |
| 010 | Medical devices, namely, infusion and injection devices for administering therapeutic agents for the treatment of disease, and pouches and mounts used therewith; medical devices, namely, infusion pumps for delivering measured amounts of solutions into the bloodstream over time for the treatment of disease; medical apparatus for monitoring blood analyte levels for use in connection with a device for the delivery of therapeutic agents for the treatment of disease; implantable subcutaneous devices for the delivery of therapeutic agents for the treatment of disease, sold empty in the nature of medical fluid injectors; on-body medical fluid injectors for the delivery of therapeutic agents for the treatment of disease; chronic disease management devices in the nature of medical sensors for use in connection with a device for the delivery of therapeutic agents for the treatment of disease that are implanted or inserted into the human body used to continuously gather human biometric data for monitoring the concentration of analytes in the human body and also including accessories therefor, namely, receivers, sensor housings and sensor insertion devices sold as a unit; medical infusion sets comprised of infusion tubing, infusion needles, needle guards, connectors, attachment clips, and accessories therefor, all used for the delivery of therapeutic agents for the treatment of disease | ACTIVE | — |
| 035 | Providing a trade-in program for drug delivery and chronic disease management devices; Pharmaceutical services, namely, mail order pharmacy services and processing online and telephone prescription orders in retail and central fill pharmacies featuring chronic disease management supplies, medications, drugs and other prescriptions | ACTIVE | — |
| 041 | Educational services, namely, creating and developing web-based and in person classes, seminars, workshops and programs in the field of managing and living with chronic disease; personalized training and coaching in the use of monitoring devices and infusion pumps in the treatment of chronic disease; training of healthcare providers in chronic disease treatment and the use of infusion pumps and infusion sets | ACTIVE | — |
| 042 | Software-as-a-service (SAAS) featuring software for use in the acquisition, capture, processing, presentation, transmission and storage of medical and physiological data obtained from medical sensors that are implanted or inserted into the human body; Providing an interactive web site featuring technology that enables users to enter, access, track, monitor and generate health and medical information and reports relating to managing chronic disease, medication and analyte levels; Upgrading of computer software, namely, Software as a Medical Device (SaMD) for predicting blood analyte levels and adjusting infusion pump settings based on personalized data for use in connection with a device for the delivery of therapeutic agents for the treatment of disease | ACTIVE | — |
| 044 | Interactive medical monitoring and alert services for reminding infusion pump users of medicinal dosage for medical treatment purposes in the nature of monitoring and managing chronic disease; Providing medical information to infusion pump users for use in connection with a device for the delivery of therapeutic agents for the treatment of disease in the form of reports in the field of chronic disease management; Providing a website featuring general medical information related to chronic diseases, including advice on treatment options and chronic disease management; providing online searchable medical databases in the field of chronic disease management for patients, their families and caregivers, and healthcare practitioners; medical consultation services, namely, patient ambassador program to communicate medical information to people with chronic disease, all of the foregoing related to use of a device for the delivery of therapeutic agents for the treatment of disease | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by DEKA Research & Development Corp.
- Other trademarks owned by DEKA Research & Development Corp.
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 035
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named SEQUEL
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 4, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 3, 2026 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Sep 3, 2026 | EXT3 | SOU EXTENSION 3 FILED | — |
| Sep 3, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 28, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 27, 2026 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Feb 27, 2026 | EXT2 | SOU EXTENSION 2 FILED | — |
| Feb 27, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 9, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 8, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 8, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 8, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 18, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Feb 3, 2025 | TMBN | TTAB RELEASE CASE TO TRADEMARKS | — |
| Feb 3, 2025 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Feb 3, 2025 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| Aug 26, 2024 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Aug 26, 2024 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Mar 23, 2024 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Mar 4, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 27, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 7, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 7, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 24, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 24, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 24, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 24, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 24, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 24, 2024 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Dec 19, 2023 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Dec 5, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 30, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 30, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 30, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 29, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 29, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 29, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 28, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 16, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 2, 2023 | NWAP | NEW APPLICATION ENTERED | — |